С января 2012 года "Биоклиник" начниает лечение больных ишемической болезнью сердца и постинфарктных больных методом клеточной терапии. Предварительное 3-х годичное наблюдение за такими больными показало снижение функционального класса стенокардии и снижение потребности в лекарствах, при высоком качестве жизни.
Лечение больных РС будет производится циклами строго с 20-го по 30-е число каждого месяца. Просим бронировать места заблаговременно.
Gene Therapy May Be Powerful New Treatment for Major Depression Researchers say animal and human data suggest gene therapy to the brain may be able to treat patients with major depression who do not respond to traditional drug treatment. [Press release from the Weill Cornell Medical College discussing online prepublication in Science Translational Medicine]
Scientists Show TAp63 Suppresses Cancer Metastasis Long overshadowed by p53, its famous tumor-suppressing sibling, the p63 gene does the tougher, important job of stifling the spread of cancer to other organs. [Press release from The University of Texas MD Anderson Cancer Center discussing online prepublication in Nature]
PiggyBac Joins Armory in Fight Against Cancer Researchers have developed a genetic tool in mice to speed the discovery of novel genes involved in cancer. The system - called PiggyBac - has already been used by the team to identify novel candidate cancer-causing genes. [Press release from the Wellcome Trust Sanger Institute discussing online prepublication in Science]
Scientists Turn Stem Cells into Cells for Cartilage Repair Researchers took human embryonic stem cells and developed a culture procedure involving a precise sequential program of conditions to specifically produce chondrocytes. [Press release from The University of Manchester discussing online prepublication in Nature Biotechnology]
Not All Stem Cells the Same, Say Researchers Until now it's been thought that human stem cell lines are all identical and possess the same ability to differentiate. But new research has shown there are subsets of stem cells that respond differently depending on what stem cell properties are measured and what test is used. [Press release from McMaster University discussing online prepublication in Nature Methods]
Promise of Outpatient Brain Gene Therapy Is One Step Closer Researchers describe how they can transfer genes into brain neurons intravenously, using a viral gene delivery vehicle that causes no side effects. [Press release from Thomas Jefferson University discussing online prepublication in Nature Methods]
Scientists Uncover Strategy to Effectively Target Drug Resistant Childhood Cancers Motivated by a pressing need to find new treatments for high-risk childhood sarcomas, scientists used cutting-edge gene silencing technology to identify a specific protein involved in resistance to therapies against a target called IGF1R in childhood sarcomas. [Press release from the British Columbia Cancer Agency discussing online prepublication in Cancer Research]
Promising Preclinical Data Demonstrate Anti-Tumor Activity of a Novel Cancer Target via RNA Interference Scientists identified a novel oncology target called COP1 that is over-expressed in human liver cancers and can accurately predict patient survival. They designed specific siRNA that, when delivered systemically with Tekmira's lipid nanoparticle technology, silence the COP1 gene. [Press release from Tekmira Pharmaceuticals Corporation discussing online prepublication in Cancer Research]
Somatic Cells Differentiate into Hepatocyte-Like Cells A research team at the Okayama University Graduate School of Medicine, working with colleagues at the University of Pittsburgh School of Medicine, found that mouse induced pluripotent stem (iPS) cells are able to proliferate in vitro without limits and could be cultured to become hepatocyte-like cells. [Press release from EurekAlert! discussing online prepublication in Cell Transplantation]
DNA Minivectors Provide New Gene Therapy Tool Tiny wound-up circular bits of DNA that carry a short "hairpin" of RNA could prove a solution to the quest for a non-toxic, long-lived gene therapy vector designed to silence cancer genes in tumor cells, said researchers. [Press release from the Baylor College of Medicine discussing online prepublication in Gene Therapy]
Synthetic FlexBone Could Help Speed Bone Transplant Recovery Current synthetic substitutes for bone tissue grafts rarely possess the bone-like properties needed for successful grafting and are often difficult for surgeons to manipulate in the operating room. In response to these challenges, researchers have developed an easy-to-produce, inexpensive, synthetic bone material called FlexBone. [Press release from the University of Massachusetts Medical School discussing online prepublication in Tissue Engineering Part A]
Exercise Boosts Muscle Stem Cells It turns out that endurance exercise, like running, doesn't just tone muscles, it enhances muscle stem cells too. Researchers found that the number of muscle stem cells, called satellite cells, increased after rats spent 13 weeks running on a treadmill for 20 minutes a day. [Press release from ScienceShots discussing online prepublication in PLoS One]
Bioelectrical Signals Turn Stem Cells' Progeny Cancerous Biologists have discovered that a change in membrane voltage in newly identified "instructor cells" can cause stem cells' descendants to trigger melanoma-like growth in pigment cells. The team also found that this metastatic transformation is due to changes in serotonin transport. The discovery could aid in the prevention and treatment of diseases like cancer and vitiligo as well as birth defects. [Press release from Tufts University discussing online prepublication in Disease Models and Mechanisms]
TAp63 Suppresses Metastasis Through Coordinate Regulation of Dicer and miRNAs Data provide a novel understanding of the roles of TAp63 in tumor and metastasis suppression through the coordinate transcriptional regulation of Dicer and miR-130b and may have implications for the many processes regulated by miRNAs. [Nature]
A Genome-Wide RNAi Screen Reveals Determinants of Human Embryonic Stem Cell Identity The study uncovers a wealth of novel human embryonic stem cell (hESC) regulators wherein PRDM14 exemplifies a key transcription factor required for the maintenance of hESC identity and the reacquisition of pluripotency in human somatic cells. [Nature]
Clonal Tracking of hESCs Reveals Differential Contribution to Functional Assays Using clonal tracking by retroviral integration, researchers analyzed in situ the propensity of individual human embryonic stem cells (hESCs) to contribute to different functional assays. They observed different clonal distributions in teratomas versus in vitro differentiation assays. [Nat Methods]
Efficient CNS Gene Delivery by Intravenous Injection Intravenous injection of recombinant SV40-derived viral vectors, particularly with mannitol pretreatment, resulted in extensive expression of multiple transgenes throughout the central nervous system (CNS). [Nat Methods]
Hepatic Differentiation of Mouse iPS Cells In Vitro Researchers present instant hepatic differentiation of mouse induced pluripotent stem cells using combined 3-day treatments of activin A and basic fibroblast growth factor with subsequent 8-day hepatocyte growth factor. [Cell Transplant]
Reversal of Depressed Behaviors in Mice by p11 Gene Therapy in the Nucleus Accumbens Results suggest that p11 loss in rodent and human nucleus accumbens may contribute to the pathophysiology of depression. Normalization of p11 expression within this brain region with adeno-associated virus-mediated gene therapy may be of therapeutic value. [Sci Transl Med]
Just a Flesh Wound? U.K. Science Budget Spared Deep Cuts The U.K. government's long-awaited Comprehensive Spending Review was released, and it calls for a flat science budget over the next 4 years. While inflationary costs mean that the budget will likely see a cut of about 10% in real terms over that period, this scenario is far less dramatic than rumored cuts of 20% to 30% in real cash. [HM Treasury, United Kingdom]
GSK, Fondazione Telethon and Fondazione San Raffaele to Collaborate on Gene Therapy for Rare Diseases GlaxoSmithKline PLC (GSK), Fondazione Telethon and Fondazione San Raffaele announced a new strategic alliance to research and develop novel treatments to address rare genetic disorders, using gene therapy carried out on stem cells taken from the patient's bone marrow (ex vivo). [GlaxoSmithKline Press Release]
Sanofi-aventis Establishes Research Collaboration with Harvard University Sanofi-aventis announced a research collaboration with Harvard University. The goal of the collaboration is to advance knowledge in the area of human health through basic and applied research and to promote scientific exchange between Harvard University and Sanofi-aventis. [Sanofi-aventis Press Release]
Celgene Completes Acquisition of Abraxis Celgene Corporation announced it has completed its acquisition of Abraxis BioScience, Inc. [Celgene Corporation Press Release]
Mesoblast Acquisition of U.S. Company Approved by Angioblast Stockholders Stockholders of United States adult stem cell company Angioblast Systems Inc. voted unanimously at a special stockholders' meeting in favor of becoming a wholly-owned subsidiary of publicly listed global regenerative medicine company, Mesoblast Limited. [Mesoblast Limited Press Release]
$3.7 Million to Push Cancer Discoveries Down the 'Pipeline' The Cancer Institute New South Wales has awarded the Garvan Institute's Cancer Research Program $3.7 million, research funding that should lead to improved clinical decision-making for breast, prostate and pancreatic cancer within the next 5 years. [The Garvan Institute Press Release]
Dicerna Pharmaceuticals Announces Second Close of Series B Financing Dicerna Pharmaceuticals, Inc., a second generation RNA interference company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and Dicer Substrate siRNA molecules, announced a second closing of its Series B equity financing, securing an additional $4 million and bringing the total capital raised in this round to $29 million. [Dicerna Pharmaceuticals, Inc. Press Release]
Aastrom Submits Special Protocol Assessment to FDA for Its Phase III CLI Program Aastrom Biosciences, Inc. announced that it has submitted to the U.S. Food and Drug Administration (FDA) a special protocol assessment describing the company's proposed Phase III clinical development program in critical limb ischemia (CLI). [Aastrom Biosciences, Inc. Press Release]
Aastrom Receives FDA Fast Track Designation for Phase III CLI Program Aastrom Biosciences, Inc. announced that the U.S. Food & Drug Administration (FDA) has granted fast track designation for the company's critical limb ischemia (CLI) cell therapy development program. [Aastrom Biosciences, Inc. Press Release]
Ceregene Initiates a New Controlled Phase IIb Trial of CERE-120 for Parkinson's Disease Ceregene, Inc. announced that enrollment has begun in a new double-blind sham surgery-controlled Phase IIb study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. [Ceregene, Inc. Press Release]
NIH Recovery Act Awards Enable Crucial Health Research Technologies Thanks to the Recovery Act, more health scientists now will have access to state-of-the-art devices, the National Institutes of Health announced. Through its National Center for Research Resources, NIH has awarded $300 million in shared instrumentation grants.
FDA Writes Prescription for IT Innovation The Food and Drug Administration is prioritizing IT as part of its five-year strategic plan, including accelerating a program to build innovative devices to improve field and laboratory analysis.
